4-(3-chloro-4-fluorophenylamino)-6-hydroxy-7-methoxyquinazoline(O-Desmorpholinopropyl Gefitinib) is a metabolite of Gefitinib, which is a potent inhibitor of tyrosine phosporylation in EGFR. Its another application is used to prepare a series of l F-18 labeled 4-aminoquinazoline derivatives for Potential PET imaging agents for tumor detection.
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer. 
Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man.
Synthesis and evaluation of novel F-18 labeled 4-aminoquinazoline derivatives: Potential PET imaging agents for tumor detection. 
 M. Ranson, et al. J. Clin. Oncol., 2002, 20(9), PP2240-2250.
 J. Mendelsohn, J.Basega,J. Clin. Oncol.,2003, 21(4),pp2781-2799.
 D. Mckillop, et al, Xenobiotica, 2004, 34(10), pp917-934.
 Y. Chen, et al, Bioorg. Med. Chem. Lett., 2012, 22(14), pp4745-4749.
NONH for all modes of transport
1. Product Specification
2. Safety Data Sheet
Please inquire for pricing and availability of this product by writing email email@example.com.